醫渡科技(02158.HK)：超額配股權獲悉數行使 涉及2346.75萬股新股份
格隆匯 2 月 8日丨醫渡科技(02158.HK)公佈，招股章程及日期為2021年1月14日的發售價格及配發結果公吿內所述的超額配股權已於2021年2月6日獲聯席全球協調人(代表國際包銷商)悉數行使，涉及合共2346.75萬股新股份，相當於全球發售項下初步可供認購發售股份(於任何超額配股權獲行使前)的約15%，以補足國際發售的超額分配。
公司將按每股發售股份26.30港元(不包括1%經紀佣金、0.0027%證監會交易徵費及0.005%香港聯交所交易費)(即全球發售下每股發售股份的發售價)發行及配發超額配發股份。
經扣除公司就行使超額配股權已付或應付的包銷佣金及估計開支後，公司將就發行超額配發股份額外收取所得款項淨額約5.925億港元。
全球發售的穩定價格期於2021年2月6日(即遞交香港公開發售申請的截止日期起計第30日)結束。高盛(亞洲)有限責任公司(作為穩定價格經辦人)透過其聯屬人士或代其行事的任何人士於穩定價格期進行的穩定價格活動為：
(1)在國際發售中超額分配合共2346.75萬股發售股份，相當於全球發售項下初步可供認購發售股份總數(於任何超額配股權獲行使前)的約15%；
(2)穩定價格經辦人根據借股協議自控股股東Sweet Panda Limited借入合共2346.75萬股股份，以補足國際發售中的超額分配。根據借股協議的條款，有關股份將歸還並重新交付予Sweet Panda Limited；及
(3)聯席全球協調人(代表國際包銷商)於2021年2月6日按發售價悉數行使超額配股權，涉及超額配發股份，相當於全球發售項下初步可供認購發售股份總數(於任何超額配股權獲行使前)的約15%，以補足國際發售的超額分配。
董事確認，緊隨穩定價格期結束後，公眾持有的已發行股份數目將符合上市規則第8.08(1)條所述的最低百分比規定，且公司將繼續遵守公眾持股量規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
